May. 12 at 7:54 AM
$CPRX
The numbers are in, and Catalyst Pharmaceuticals (CPRX) continues to show its strength in the rare disease market. For the first quarter of 2026, the company reported a total revenue of
$149.4 million, which was a solid beat over analyst expectations. This growth was largely powered by their two lead drugs: Firdapse, which treats a rare muscle disorder, and Agamree, a specialized treatment for Duchenne muscular dystrophy. Even with their seizure medication, Fycompa, facing a dip from generic competition, the overall portfolio remains highly profitable with a GAAP net income of
$63.7 million.
The landscape for CPRX has changed recently due to the announcement that Angelini Pharma will acquire the company for
$31.50 per share in cash. This
$4.1 billion deal is expected to close in the third quarter of 2026. Because the buyout price is now fixed, the stock price is "anchored" near that
$31.50 mark and there is little room for the stock price to climb higher than that price.
